Cecilia Brown

Articles by Cecilia Brown

Cecilia BrownAcute Myeloid Leukemia | March 23, 2023
The 60-day mortality rate was around twice as high in patients with KMT2A rearrangement.
Read More
Cecilia BrownAcute Myeloid Leukemia | March 23, 2023
While NPM1 mutations impacted CR rates, they had “no impact” on RFS and OS after each line of salvage therapy.
Cecilia BrownAggressive B-Cell Lymphoma | March 22, 2023
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in relapsed or refractory LBCL.
Sandy Wong, MDMyeloma | March 22, 2023
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Cecilia BrownMyeloma | March 22, 2023
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Cecilia BrownAcute Myeloid Leukemia | March 21, 2023
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
Cecilia BrownMyelofibrosis | March 21, 2023
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
Cecilia BrownAcute Myeloid Leukemia | March 21, 2023
A new study suggests CR with MRD negativity should be the “key objective" of high- and low-intensity therapy for AML.
Sandy Wong, MDMyeloma | March 20, 2023
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Cecilia BrownMyelofibrosis | March 16, 2023
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
Cecilia BrownMyeloma | March 15, 2023
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Sandy Wong, MDMyeloma | March 14, 2023
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
Cecilia BrownMyeloma | March 14, 2023
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
Cecilia BrownMantle Cell Lymphoma | March 13, 2023
A phase I/II trial of LV20.19 showed a 100% ORR in patients with relapsed or refractory MCL.
Cecilia BrownMantle Cell Lymphoma | March 13, 2023
Benefits of rituximab maintenance were observed despite the shift in first-line induction strategies over the years.
Cecilia BrownMyeloma | March 10, 2023
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Cecilia BrownMantle Cell Lymphoma | March 7, 2023
Brexucabtagene autoleucel in the standard-of-care setting for R/R MCL showed efficacy and toxicity “consistent” with ...
Cecilia BrownMyelodysplastic Syndromes | March 6, 2023
Treatment of LR-MDS remains an unmet need and goals of therapy should extend beyond transfusion independence.
Cecilia BrownMyeloma | March 6, 2023
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
Cecilia BrownMyeloma | March 6, 2023
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.